Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH (BEST)

Civil Hospices of Lyon

Status: Completed

Conditions: HHT; Hemorrhagic Hereditary Telangiectasia

Treatments: Other: bevacizumab treatment

Study type: Observational

Funder types: Other

Identifiers

NCT06039124

69HCL21_1438

Details and patient eligibility

About

Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT.

We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment.

We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient included in BABH study

Exclusion criteria

• Patients opposition

Trial design

23 participants in 1 patient group

HHT patients previously included in BABH study

Description:

Clinical and therapeutic follow-up of HHT patients for one year after the end of a clinical trial using bevacizumab.

Treatment:

Other: bevacizumab treatment